Prof. Howard Lee was invited to a session at the Spring Conference, 2021, organized and sponsored by The Pharmaceutical Society of Korea, April 22, 2021, held in the K-Hotel, Seoul, Korea. In the session, Prof. Lee introduced the audience to a dimension reduction model that CCADD has developed to make clinical trial feasibility assessments efficient, practical, and realistic. The research project has been supported for three years by the National Research Foundation of Korea, which is expected to end by this year. Based on the positive results of the research, particularly in the area of type II diabetes mellitus, a patent has been filed, and CCADD plans to expand it to other disease areas too. Prof. Lee has emphasized in the session that artificial intelligence technologies can and should be applied to clinical drug development to make it more versatile and agile. His talk was well-received. 

Prof. Howard Lee was invited to speak at an educational seminar and an international symposium, both sponsored by the Pharmaceutical Society of Korea, in association of its spring convention, held in the Millennium Hilton Seoul, Korea, on April 25-26. The PSK is an academic organization representing pharmacy since its foundation in 1946, which has grown into the biggest institution for pharmacists in Korea. In the educational seminar, Prof. Lee talked about how bio-big data can be used for the efficient planning and conduct of clinical drug development. His talk was based on his experience and lessons learned in the two recent research projects that CCADD led and will be actively participating, i.e., ACTRiS and SUCCESS. His presentation has received media attention as summarized in a newspaper article.   

The international symposium was held on the second day of the convention. Prof. Lee introduced the audience to several possible applications of artificial intelligence (AI) to clinical trials, with a special focus on a CCADD research project using feature selection for clinical trial feasibility. This symposium was organized by Prof. Hwi-yeol Yun, Chungnam National University College of Pharmacy, a long-time friend and collaborator of Prof. Lee's.   

Lee JM, Lee JH, Kim JK, Shin HJ, Lee H, Lee SJ, Hong CI. Pharmacokinetic Study of CKD-602, A New Camptothecin Derivative: Distribution, Metabolism and Excretion. Journal of the Pharmaceutical Society of Korea, 1998;42(4):437-46.

Lee JM, Lee JH, Kim JK, Shin HJ, Lee H, Lee SJ, Hong CI. Pharmacokinetic Study of CKD-602, A New Camptothecin Derivative: Absorption. Journal of the Pharmaceutical Society of Korea, 1998;42(4):431-36.